Analyst consensus rating
Nautilus Biotechnology Analyst Rating: none
NAUT is rated none by 1 analysts with a $4.00 target. As of 2026-09-03.
Direct answer
Nautilus Biotechnology's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.00.
Forecast evidence checked September 3, 2026.
Get free Nautilus Biotechnology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.91
- Average price target
- $4.00
- High price target
- $4.00
- Low price target
- $4.00
- Low target gap
- +338.6%
- Target upside
- +338.6%
- High target gap
- +338.6%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- September 3, 2026
- Valid through
- September 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Nautilus Biotechnology?
Nautilus Biotechnology has a verified none consensus. The same dataset has an average price target of $4.00.
How far are Nautilus Biotechnology's low and high targets from the recorded price?
The low target implies +338.6%, while the high target implies +338.6%.
How many analysts are included in Nautilus Biotechnology's consensus?
The verified consensus includes 1 analysts.
How is Nautilus Biotechnology's target upside or downside calculated?
The average target of $4.00 is divided by the recorded price of $0.91, then one is subtracted to produce +338.6%. This does not guarantee a future return.
When was Nautilus Biotechnology's analyst forecast verified?
The data was verified on 2026-09-03. The dataset is valid through 2026-09-10.